checkAd

     1476  0 Kommentare Liver Fibrosis Therapeutic Development and Pipeline Review H1 2017 Research Report Now Available at RnRMarketResearch

    PUNE, India, May 23, 2017 /PRNewswire/ --

    RnRMarketResearch.com adds "Liver Fibrosis - Pipeline Review, H1 2017" therapeutic market research report of 200 pages with latest updates, data and information to its online business intelligence library.

    The report "Liver Fibrosis - Pipeline Review, H1 2017" provides comprehensive information on the therapeutics under development for Liver Fibrosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    Liver fibrosis is a scarring process which results in inflammation and liver cell death. Symptoms include abdominal pain, easy bruising, lack of appetite, nausea, tenderness and enlargement of the liver, weight loss and yellowing of skin and eyes. Risk factors include age, heavy alcohol consumption, and chronic infection with hepatitis B or C virus and weakened immune system.

    Complete report is available @ http://www.rnrmarketresearch.com/liver-fibrosis-pipeline-review-h1-2017-market-report.html .

    Liver Fibrosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Companies discussed in this report include  AdAlta Ltd, Advinus Therapeutics Ltd, Allergan Plc, Angion Biomedica Corp, Asubio Pharma Co Ltd, aTyr Pharma Inc, Beijing Kawin Technology Share-Holding Co Ltd, BioLineRx Ltd, Bioneer Corp, BiOrion Technologies BV, Bird Rock Bio Inc, Cellmid Ltd, ContraVir Pharmaceuticals Inc, Dicerna Pharmaceuticals Inc, Dr. Falk Pharma GmbH, Dynavax Technologies Corp, Evotec AG, Galectin Therapeutics Inc, Genfit SA, GenKyoTex SA, GNI Group Ltd, HanAll Biopharma Co Ltd, HEC Pharm Co Ltd, Immuron Ltd, Intercept Pharmaceuticals Inc, INVENT Pharmaceuticals Inc, Isarna Therapeutics GmbH, KineMed Inc, Nitto Denko Corp, Pfizer Inc, Pharmaxis Ltd, Promedior Inc, Promethera Biosciences SA, ProMetic Life Sciences Inc, Ribomic Inc, RXi Pharmaceuticals Corp, Samumed LLC, Silence Therapeutics Plc, Sirnaomics Inc, TaiwanJ Pharmaceuticals Co Ltd, TCM Biotech International Corp, TRACON Pharmaceuticals Inc, Vascular Biogenics Ltd, Virobay Inc plc, and XTuit Pharmaceuticals Inc.

    Seite 1 von 2


    PR Newswire (engl.)
    0 Follower
    Autor folgen
    Verfasst von PR Newswire (engl.)
    Liver Fibrosis Therapeutic Development and Pipeline Review H1 2017 Research Report Now Available at RnRMarketResearch PUNE, India, May 23, 2017 /PRNewswire/ - RnRMarketResearch.com adds "Liver Fibrosis - Pipeline Review, H1 2017" therapeutic market research report of 200 pages with latest updates, data and information to its online business intelligence library. …